Table 3. Reduction of WOMAC pain, WOMAC stiffness, WOMAC function, WOMAC score, and Lequesne index in patients after the 6th month.
| WOMAC OA † after the 6th month | N | change x̄ and MIN-MAX | ||
|---|---|---|---|---|
| WOMAC pain | CGS‡ | 47 | 5.29 (-5.0-16.0) | U=722, * p<0.01 |
| NSAID§ | 46 | 2.78 (-5.0-11.0) | ||
| total | 93 | 4.05 (-5.0-16.0) | ||
| WOMAC stiffness | CGS | 46 | 2.13 (-4.0-7.0) | U=877, * p>0.05 |
| NSAID | 45 | 1.56 (-3.0-6.0) | ||
| total | 91 | 1.85 (-4.0-7.0) | ||
| WOMAC function | CGS | 47 | 15.62 (-7.0-41.0) | U=749, * p<0.01 |
| NSAID | 46 | 8.72 (-8.0-34) | ||
| total | 93 | 12.2 (-8.0-41.0) | ||
| total WOMAC score | CGS | 46 | 23.23 (-2.0-58.0) | U=699, * p<0.01 |
| NSAID | 45 | 13. 29 (-6.0-41.0) | ||
| total | 91 | 18.31 (-6.0-58.0) | ||
| Lequesne after the 6th month | CGS | 46 | 5.16 (0.5-10.5) | U=541, * p<0.01 |
| NSAID | 46 | 2.41 (-6.0-9.5) | ||
| Total | 92 | 3.78 (-6.0-9.5) | ||
*U=Mann Whitney test; †WOMAC OA Index – Western Ontario and McMaster Universities Osteoarthritis Index; ‡CGS – crystalline glucosamine sulfate; §NSAID – nonsteroidal anti-inflammatory drug